Literature DB >> 18663051

Solid variant of primary effusion lymphoma in successfully treated HIV infection: a case report.

E Mylona1, I G Baraboutis, O Georgiou, D Rondogianni, L J Lekakis, V Papastamopoulos, I Apostolidis, A T Skoutelis.   

Abstract

Primary effusion lymphoma (PEL) is a unique form of non-Hodgkin lymphoma, mainly met in severely immunocompromised, HIV-positive patients. PEL is aetiologically related to human herpes virus-8 (HHV-8) and it usually presents as a lymphomatous body cavity effusion in the absence of a solid tumour mass. Recently, cases of HIV-positive patients with HHV-8-positive solid tissue lymphomas, not associated with an effusion, have been reported (solid variant of PEL). The prognosis of PEL is reported to be poor. We report a case of an HIV-positive patient with a typical solid variant of PEL without effusion. Interestingly, his disease developed while being on stable antiretroviral therapy (ART) with high CD4 counts. He had a relatively long survival with chemotherapy and ART.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18663051     DOI: 10.1258/ijsa.2007.007285

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  5 in total

1.  HIV-associated primary effusion lymphoma presenting as a paracardial mass.

Authors:  Heather Katz; Cielo Rose; Nina Thakker Rivera; Natasha Bray
Journal:  BMJ Case Rep       Date:  2015-02-27

Review 2.  Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.

Authors:  William R Foster; Alina Bischin; Russell Dorer; David M Aboulafia
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-04-01

3.  Kaposi's Sarcoma-Associated Herpesvirus-Related Solid Lymphoma Involving the Heart and Brain.

Authors:  Jason R Andrews; Yoon Andrew Cho-Park; Judith Ferry; Jeremy S Abramson; Gregory K Robbins
Journal:  AIDS Res Treat       Date:  2011-04-03

4.  Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome.

Authors:  Mark N Polizzotto; Thomas S Uldrick; Duosha Hu; Robert Yarchoan
Journal:  Front Microbiol       Date:  2012-03-02       Impact factor: 5.640

5.  A KSHV microRNA enhances viral latency and induces angiogenesis by targeting GRK2 to activate the CXCR2/AKT pathway.

Authors:  Wan Li; Xuemei Jia; Chenyou Shen; Mi Zhang; Jingyun Xu; Yuancui Shang; Kaixiang Zhu; Minmin Hu; Qin Yan; Di Qin; Myung-Shin Lee; Jianzhong Zhu; Hongmei Lu; Brian J Krueger; Rolf Renne; Shou-Jiang Gao; Chun Lu
Journal:  Oncotarget       Date:  2016-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.